Michael Mackenzie Lee Dore

Conference Journal of Clinical Oncology · February 2025 101Background: In 2024, incidence and mortality cases related to colorectal cancer (CRC) in the US are estimated to reach 152 ... Full text Cite

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023.

Conference Journal of Clinical Oncology · February 2025 102Background: Colorectal cancer (CRC) is the third most common cancer in the United States and the second most common cause ... Full text Cite

Multi-target stool-DNA test for colorectal cancer screening and effects on health and economic outcomes compared to blood-based tests: Influence of adherence.

Conference Journal of Clinical Oncology · February 2025 88Background: There are an estimated 60 million individuals in the US who are not up-to-date with average-risk colorectal can ... Full text Cite

Trends in utilization of colorectal cancer screening modalities among patients with average risk in the United States from 2017 to 2023.

Conference Journal of Clinical Oncology · February 2025 98Background: Colorectal cancer (CRC) is the second leading cause of cancer mortality in the US. The national CRC screening r ... Full text Cite

Comparison of screening outcomes associated with advanced precancerous lesion versus colorectal cancer sensitivity for a blood-based test: A simulation study.

Conference Journal of Clinical Oncology · February 2025 89Background: With estimates of over 150,000 incident and 50,000 fatal colorectal cancer (CRC) cases in 2024, efforts are ong ... Full text Cite

Real-world multi-target stool DNA longitudinal adherence for colorectal cancer rescreening in a large, national population

Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2024 Link to item Cite